These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 29412643

  • 21. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y, Zhou S, Deng Q, Li X, Meng J, Guan Y, Li C, Xiao C.
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [Abstract] [Full Text] [Related]

  • 22. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.
    Sarathy JP, Xie M, Jones RM, Chang A, Osiecki P, Weiner D, Tsao WS, Dougher M, Blanc L, Fotouhi N, Via LE, Barry CE, De Vlaminck I, Sherman DR, Dartois VA.
    mBio; 2023 Apr 25; 14(2):e0059823. PubMed ID: 37017524
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Virtual screening for the identification of novel inhibitors of Mycobacterium tuberculosis cell wall synthesis: inhibitors targeting RmlB and RmlC.
    Ren JX, Qian HL, Huang YX, Zhu NY, Si SY, Xie Y.
    Comput Biol Med; 2015 Mar 25; 58():110-7. PubMed ID: 25637777
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C, Mehra R, Sharma R, Chib R, Wazir P, Nargotra A, Khan IA.
    Tuberculosis (Edinb); 2015 Dec 25; 95(6):664-677. PubMed ID: 26318557
    [Abstract] [Full Text] [Related]

  • 33. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH, Smith PW.
    Bioorg Med Chem; 2015 Aug 15; 23(16):5087-97. PubMed ID: 25577708
    [Abstract] [Full Text] [Related]

  • 34. Inhibiting Mycobacterium tuberculosis within and without.
    Cole ST.
    Philos Trans R Soc Lond B Biol Sci; 2016 Nov 05; 371(1707):. PubMed ID: 27672155
    [Abstract] [Full Text] [Related]

  • 35. Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery.
    Perveen S, Sharma R.
    Biochem Pharmacol; 2022 Mar 05; 197():114906. PubMed ID: 34990594
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development.
    Chae H, Shin SJ.
    J Microbiol; 2018 May 05; 56(5):300-311. PubMed ID: 29721826
    [Abstract] [Full Text] [Related]

  • 38. Type-II NADH Dehydrogenase (NDH-2): a promising therapeutic target for antitubercular and antibacterial drug discovery.
    Sellamuthu S, Singh M, Kumar A, Singh SK.
    Expert Opin Ther Targets; 2017 Jun 05; 21(6):559-570. PubMed ID: 28472892
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.